SWM
TEVA icon

SHP Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

SHP Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.92K Sell
163
-10
-6% -$322 ﹤0.01% 1075
2025
Q4 		$5.41K Buy
+173
New +$4.26K ﹤0.01% 968

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SHP Wealth Management's TEVA Position: Q1 2026 in Review

SHP Wealth Management reduced its Teva Pharmaceuticals (TEVA) stake by 5.8% in Q1 2026, selling an estimated $322 and leaving 163 shares worth $4.92K. The position accounts for ﹤0.01% of the portfolio, ranked #1075.

SHP Wealth Management first reported a position in TEVA in Q4 2025 and has held it in 2 quarters since. The position peaked at $5.41K in Q4 2025. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • SHP Wealth Management held 163 shares of Teva Pharmaceuticals worth $4.92K as of Q1 2026.
  • SHP Wealth Management sold 10 Teva Pharmaceuticals shares in Q1 2026, an estimated $322.
  • Teva Pharmaceuticals made up ﹤0.01% of SHP Wealth Management's portfolio in Q1 2026, its #1075 holding.
  • SHP Wealth Management first reported a position in Teva Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • SHP Wealth Management's Teva Pharmaceuticals position peaked at $5.41K in Q4 2025.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on SHP Wealth Management's 13F filing for Q1 2026, filed 8 May 2026.